This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
by Zacks Equity Research
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
by Zacks Equity Research
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
by Kinjel Shah
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Here's Why Moderna Stock Soared 16% on Wednesday
by Zacks Equity Research
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
by Kinjel Shah
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
by Zacks Equity Research
Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.
What Makes BioNTech (BNTX) a New Buy Stock
by Zacks Equity Research
BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
by Zacks Equity Research
PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.
Alphabet and Amazon Report: Global Week Ahead
by John Blank
With upcoming earnings reports from "Mag 7" members Alphabet (GOOGL) on Tuesday and Amazon (AMZN) on Thursday, investors will have the chance to determine whether recent AI market volatility is a warning.
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Here's How to Play Pfizer Stock Before Q4 Earnings Release
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death
by Sundeep Ganoria
The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
by Zacks Equity Research
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
by Zacks Equity Research
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS
by Sundeep Ganoria
President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
by Zacks Equity Research
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.